BSP Receives FDA Approval For HyperQ Rest System

October 29, 2014 | BSP, the Israeli company developing non-invasive methods for the detection of heart disease, received Food & Drug Administration approval to market and sell its HyperQ Rest System. The system is intended to aid in the diagnosis of patients with chest pain in the emergency room and is meant for use in ECG testing. The FDA approved the use of the device based on clinical trials conducted in emergency departments for the diagnosis of Acute Coronary Syndrome (ACS) in patients with acute chest pain. The HyperQ technology developed by the company enables advanced diagnostics means with high diagnostic value for detection of heart disease in the early stages, saving invasive and radioactivity tests.